Literature DB >> 15610672

African Trypanosomiasis: Changing Epidemiology and Consequences.

Jean-Paul Chretien1, Bonnie L Smoak.   

Abstract

Human African trypanosomiasis has re-emerged as a serious public health threat after near-elimination because of diminished investment in previously successful control programs. The continued, occasional importation of African trypanosomiasis to the United States can be expected as tourists and immigrants travel from high-risk areas. No vaccine or chemoprophylaxis is available for this disease, and travelers to affected areas should be counseled on tsetse fly avoidance. New diagnostic and staging tests are promising but have not replaced the classical method of examining body fluids for trypanosomes. Prompt diagnosis and staging is essential because if untreated, East African and West African sleeping sickness are fatal. Drug regimens are toxic and cumbersome, and short-term prospects for therapeutic advances are limited.

Entities:  

Year:  2005        PMID: 15610672     DOI: 10.1007/s11908-005-0024-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  30 in total

Review 1.  Human African trypanosomiasis of the CNS: current issues and challenges.

Authors:  Peter G E Kennedy
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.

Authors:  J Pépin; F Milord; A Khonde; T Niyonsenga; L Loko; B Mpia
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Jul-Aug       Impact factor: 2.184

Review 3.  The treatment of human African trypanosomiasis.

Authors:  J Pépin; F Milord
Journal:  Adv Parasitol       Date:  1994       Impact factor: 3.870

4.  A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis.

Authors:  E Magnus; T Vervoort; N Van Meirvenne
Journal:  Ann Soc Belg Med Trop       Date:  1978

5.  Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.

Authors:  D Legros; S Evans; F Maiso; J C Enyaru; D Mbulamberi
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

6.  Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.

Authors:  C Burri; J Keiser
Journal:  Trop Med Int Health       Date:  2001-05       Impact factor: 2.622

7.  Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.

Authors:  C Schmid; S Nkunku; A Merolle; P Vounatsou; C Burri
Journal:  Lancet       Date:  2004 Aug 28-Sep 3       Impact factor: 79.321

Review 8.  The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.

Authors:  V Lejon; M Boelaert; J Jannin; A Moore; P Büscher
Journal:  Lancet Infect Dis       Date:  2003-12       Impact factor: 25.071

9.  Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire.

Authors:  V Jamonneau; P Solano; A Garcia; V Lejon; N Djé; T W Miezan; P N'Guessan; G Cuny; P Büscher
Journal:  Trop Med Int Health       Date:  2003-07       Impact factor: 2.622

10.  Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study.

Authors:  J Robays; A Ebeja Kadima; P Lutumba; C Miaka mia Bilenge; V Kande Betu Ku Mesu; R De Deken; J Makabuza; M Deguerry; P Van der Stuyft; M Boelaert
Journal:  Trop Med Int Health       Date:  2004-08       Impact factor: 2.622

View more
  2 in total

Review 1.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

2.  Changes in haematological indices and protein concentrations in Trypanosoma brucei infected rats treated with homidium chloride and diminazene aceturate.

Authors:  Faoziyat Adenike Sulaiman; Oluyomi Stephen Adeyemi
Journal:  EXCLI J       Date:  2010-02-16       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.